Since I first highlighted Neovasc (OTCPK:NVCIF) in an article published last month, the stock has jumped more than 50% and the company announced several bullish updates that make an even stronger case for why this severely undervalued medical device company should be trading at much higher valuations.
Neovasc is developing two groundbreaking devices for the cardiovascular space, and has a profitable core operating business that produces tissue like leaflets for aortic heart valves and stents. Phillip Frost and his company OPKO Health (OPK) both have a stake in Neovasc.
My SeekingAlpha article was published on October 28th (A).
On October 29th (B), Neovasc presented at the 2013 TCT in San Francisco...
Only subscribers can access this article, which is part of the PRO research library covering 3,570 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: